Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Lyell Immunopharma, Inc. | Chief General Counsel | Option (right to buy) | 300K | Mar 16, 2022 | Direct | ||
Terns Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 64K | Nov 18, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TERN | Terns Pharmaceuticals, Inc. | Nov 18, 2024 | 1 | $0 | 4 | Nov 19, 2024 | Director |
TERN | Terns Pharmaceuticals, Inc. | Nov 18, 2024 | 0 | $0 | 3 | Nov 19, 2024 | Director |
LYEL | Lyell Immunopharma, Inc. | Mar 16, 2022 | 1 | $0 | 4 | Mar 18, 2022 | Chief General Counsel |
LYEL | Lyell Immunopharma, Inc. | Jun 16, 2021 | 0 | $0 | 3 | Jun 16, 2021 | Chief General Counsel |